A comparison between three commercial kits for chromogranin A measurements.

Chromogranin (CgA) has been shown to be an excellent marker for neuroendocrine tumours. There are now three commercial assays on the market. We wanted to compare the usefulness of the different kits in a clinical situation. We have thus measured CgA in 77 patients and compared the results from the different methods. CgA was measured with three different commercial kits according to the recommendations from the manufacturers (CGA-RIA CT; CIS bio international, Gif-sur-Yvette cedex, France, DAKO Chromogranin A ELISA kit; DAKO A/S, Glostrup, Denmark and CgA; EuroDiagnostica, Malmö, Sweden). The sensitivity and specificity differed between the different kits. The CIS kit showed a sensitivity of 67% and a specificity of 96%. The sensitivity and specificity were both 85% for the DAKO kit and 93% and 88% respectively for the EuroDiagnostica assay. We have concluded that CgA is an important tumour marker for all neuroendocrine tumours. However, different analytical properties of the respective kits give different performances, a fact that must be taken into consideration when comparing results from different clinical studies. A recognised international standard for CgA would be a step on the way to harmonisation, but antibody selection and construction of the assays will probably still influence the results.

[1]  J. Holst,et al.  Characterization of immunoreactive pancreastatin in porcine tissues. , 1991, Scandinavian journal of clinical and laboratory investigation.

[2]  D. O'Connor,et al.  Chromogranin A in uremia: progressive retention of immunoreactive fragments. , 1990, Kidney international.

[3]  E. Krenning,et al.  Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. , 1997, The Journal of clinical endocrinology and metabolism.

[4]  A. Laslop,et al.  Proteolytic processing of chromogranins. , 2000, Advances in experimental medicine and biology.

[5]  R. Bouillon,et al.  Chromogranin A: its clinical value as marker of neuroendocrine tumours , 1998, European journal of clinical investigation.

[6]  M. P. Canale,et al.  Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. , 1994, The Journal of clinical endocrinology and metabolism.

[7]  D. Jonkers,et al.  Serum chromogranin A as a screening test for gastric enterochromaffin‐like cell hyperplasia during acid‐suppressive therapy , 2001, European journal of clinical investigation.

[8]  K. Helle,et al.  Recombinant human chromogranin A: expression, purification and characterization of the N-terminal derived peptides , 1995, Regulatory Peptides.

[9]  E. Seregni,et al.  Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors , 1999, Cancer.

[10]  C. Shaw,et al.  Distribution and partial characterisation of immunoreactivity to the putative C-terminus of rat pancreastatin , 1990, Regulatory Peptides.

[11]  U. Hellman,et al.  Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. , 1993, The Journal of endocrinology.

[12]  M. Stridsberg,et al.  Selective Processing of Chromogranin A in the Different Islet Cells in Human Pancreas , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[13]  A. J. Man in 't Veld,et al.  Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[14]  P. Erba,et al.  Chromogranin-A as a Serum Marker for Neuroendocrine Tumors: Comparison with Neuron-Specific Enolase and Correlation with Immunohistochemical Findings , 1999, The International journal of biological markers.

[15]  J. Bredow,et al.  Chromogranin A: an additional tumor marker for postoperative recurrence and metastases of medullary thyroid carcinomas? , 2000, Anticancer research.

[16]  M. Stridsberg,et al.  Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. , 1997, European journal of endocrinology.

[17]  L. Eiden,et al.  Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway , 1995, Regulatory Peptides.

[18]  J. Rehfeld,et al.  Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. , 1997, Scandinavian journal of gastroenterology.

[19]  M. Stridsberg.  Measurements of chromogranins and chromogranin-related peptides by immunological methods. , 2000, Advances in experimental medicine and biology.

[20]  E. Wilander,et al.  Chromogranin A in Human Neuroendocrine Tumors: An Immunohistochemical Study With Region-Specific Antibodies , 2001, The American journal of surgical pathology.

[21]  D. O'Connor,et al.  Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. , 1994, The Journal of clinical investigation.